{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.5","upperLimit":"66.1","value":"46.4"},{"groupId":"OG001","lowerLimit":"15.2","upperLimit":"64.6","value":"37.5"},{"groupId":"OG002","lowerLimit":"0.4","upperLimit":"57.9","value":"14.3"},{"groupId":"OG003","lowerLimit":"28.8","upperLimit":"48.4","value":"38.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"102"}],"units":"Participants"}],"description":"ORR is the percentage of patients with at least one visit response of CR or PR based on CT and/or PET scans evaluated by investigator per Lugano criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Group A: Open label AZD4205 at 150 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG000","title":"AZD4205 Group A"},{"description":"Group B: Open label AZD4205 at 250 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG001","title":"AZD4205 Group B"},{"description":"Group C: Open label AZD4205 at 150 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG002","title":"AZD4205 Group C"},{"description":"Group D: Open label AZD4205 at 150 mg (RP2D), once daily (Phase 2)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG003","title":"AZD4205 Group D"}],"paramType":"NUMBER","populationDescription":"Part A: Evaluable for Response Set (All dosed patients with baseline measurable disease) Part B: Evaluable for CT-based Response Set","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Part A and Part B: ORR Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"percentage of participants"}